Binex, Tongfang Rework Deal Amid Strained Korea-China Ties
Executive Summary
With Tongfang Kontafarma's cancelation of an equity investment, Binex appears to have become the first South Korean biologics firm to be hit by an increasingly strained relationship between South Korea and China. The two companies will instead establish a Chinese joint venture.
You may also be interested in...
Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea
French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.
Celltrion Gets Go-Ahead For Remsima Trials In China, Mulls JV
Celltrion has received approval to begin clinical trials of its biosimilar infliximab in China and also filed IND applications for other biosimilar products with the CFDA, accelerating plans to enter the world’s second biggest pharma market as it propels efforts for global leadership in the biosimilar space.
Aprogen’s Biosimilar Remicade To Hit Japan Next Year?
South Korea-based biotech firm Aprogen's biosimilar version of Remicade (Johnson & Johnson's infliximab) is set to complete a Phase III clinical study in Japan as early as this month. The company’s Japanese partner will then file for local regulatory approval immediately after completing the trial and aims to launch the product in the country in the latter half of next year.